Morgan DJ, Zhan M, Goto M, Franciscus C, Alexander B, Vaughan-Sarrazin M, Roghmann MC, Pineles L. The Effectiveness of Contact Precautions on Methicillin-Resistant Staphylococcus aureus in Long-term Care Across the United States. Clin Infect Dis. 2020 Oct 23;71(7):1676-1683. doi: 10.1093/cid/ciz1045. PMID: 31637429. This was a cohort study of long-term VA facilities (aka the CLC) evaluating
Tag: Article Summaries
Kullberg, Bart Jan, et al. “Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: the ACTIVE Trial.” Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 68, no. 12, 2019, pp. 1981-1989.
The ACTIVE trial! This is a phase III, RCT, double blind, multicenter, non-inferiority trial comparing isavuconazole vs caspofungin in invasive candidiasis. Folks, in ID, it doesn’t get any better than this (look at all these studies!) Exclusion criteria were Candida in any body part (i.e. osteomyelitis, IE, meningitis), severe immunodeficiency, >48hrs of other antifungal therapy.
Allen, John M., et al. “Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients With Methicillin-Susceptible Staphylococcus Aureus Infection: a Meta-Analysis With Trial Sequential Analysis.” Infectious Diseases and Therapy, vol. 8, no. 4, 2019, pp. 671-686.
This one is not groundbreaking but nice to have data supporting our decisions. This was a review of the literature evaluating the efficacy of cefazolin vs anti-staphylococcal penicillin (cloxacillin, nafcillin, flucoxacillin) in staph aureus bacteremia. The primary end point was 90d all cause mortality; secondary end point was 30d all cause mortality, treatment failure/relapse, and
Jorgensen, Sarah C J., et al. “Sequential Intravenous-to-oral Outpatient Antibiotic Therapy for MRSA Bacteraemia: One Step Closer.” The Journal of Antimicrobial Chemotherapy, vol. 74, no. 2, 2019, pp. 489-498.
This is a retrospective, observational cohort study from Detroit evaluating the frequency of IV to PO switch and the population for which this is use, as well as to figure out the factors associated with failure. They recruited 492 patients with MRSA bacteremia (basically anyone with the exception of polymicrobial bacteremia and those with wither
Chang, Euijin, et al. “Limited Positive Predictive Value of β-d-Glucan in Hematologic Patients Receiving Antimold Prophylaxis.” Open Forum Infectious Diseases, vol. 7, no. 3, 2020, pp. ofaa048.
Retrospective study from South Korea evaluating the predictive value of BD glucan in the age of mold active triazole prophylaxis. They recruited patients that underwent induction chemotherapy, SCT, or GVHD treatment that had BD glucans throughout their stay while on posa or micafungin prophylaxis. They defined a positive BD glucan as 2 or more BDG